Innovative medicines and market access agreements;Médicaments innovants et contrats d'accès au marché

Annales Pharmaceutiques Francaises

Volumn 71, Issue 5, 2013, Pages 302-325

  Toumi, M ^a   Zard, J ^a   Duvillard, R ^a   Jommi, C ^a  

^a UNIVERSITÉ LYON 1   (France)

Author keywords

Agreements; Innovation; Market access; Medicine; Performance; Price; Risk; Value

Indexed keywords

ARTICLE; CONTRACT; DRUG MARKETING; FINANCIAL MANAGEMENT; HEALTH CARE ACCESS; HEALTH CARE COST;

ACCÈS AU MARCHÉ; ACCORDS; AGREEMENTS; INNOVATION; MARKET ACCESS; MEDICINE; MÉDICAMENT; PERFORMANCE; PRICE; PRIX; RISK; RISQUE; VALEUR; VALUE;

COSTS AND COST ANALYSIS; DIFFUSION OF INNOVATION; DRUG INDUSTRY; DRUG THERAPY; FRANCE; MARKETING OF HEALTH SERVICES; TERMINOLOGY AS TOPIC;

EID: 84884588877     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharma.2013.08.005     Document Type: Article

References (20)

1. Pouvourville de G. Risk-sharing agreements for innovative drugs: a new solution to old problems?. Eur J Health Econ 2006, 3:155-157.
2. Jaroslowski S., Toumi M. Market Access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts. BMC Health Serv Res 2011, 11:259.
3. Towse A., Garrison L.P. Can't get no satisfaction? Will pay for performance help? Toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products. Pharmacoeconomics 2010, 2:93-102.
4. Adamski J., Godman B., Ofierska-Sujkowska G., Osińska B., Herholz H., Wendykowska K., et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res 2010, 10:153.
5. Toumi M., Michel M. Define access agreements 2011, Pharmaceutical Market Europe, [contrÔlé juillet 2013]. http://www.pmlive.com/Europe.
6. NHS discussion paper: coverage with evidence development in NHS Scotland Coverage with Evidence Development Workshop 2008; Glasgow.
7. Garrison L, Towse A. Performance-based risk-sharing arrangements-Good practices for design, implementation and evaluation: an ISPOR Task Force Report. [contrÔlé juillet 2013]. http://www.ispor.org/taskforces/Performance-based-risk-sharing-arrangements.asp.
8. Hutton J., Trueman P., Henshall C. Coverage with Evidence development: an examination of conceptual and policy issues. Int J Technol Assess Health Care 2007, 4:425-432.
9. Sinha G. Expensive cancer drugs with modest benefit. Ignite debate over solutions. J Natl Cancer Inst 2008, 19:1347-1349.
10. Pueg-Peiro B. The simple economics of risk-sharing agreements between the NHS and the pharmaceutical industry. Health Econ 2011, 4:461-470.
11. Boggild M., Palace J., Barton P., Ben-Shlomo Y., Bregenzer T., Dobson C., et al. Multiple sclerosis risk sharing scheme: two-year results of clinical cohort study with historical comparator. Br Med J 2009, 339:b4677.
12. Pickin M., Cooper C.L., Chater T., O'Hagan A., Abrams K.R., Cooper N.J., et al. The Multiple sclerosis risk sharing scheme monitoring study-early results and lessons for the future. BMC Neurol 2009, 9:1.
13. Carlson J.J., Sullivan S.D., Garrison L.P., Neumann P.J., Veenstra D.L. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy 2010, 3:179-190.
14. Jaroslawski, Toumi M. Market Access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts. BMC Health Serv Res 2011, 11:259.
15. Jaroslawski S., Toumi M. Design of patient access schemes in the UK: influence of health technology assessment by the National Institute for Health and Clinical Excellence. Appl Health Econ Health Policy 2011, 9:209-215.
16. Pugatch M., Healy P., Chu R. Sharing the burden: could risk-sharing change the way we pay for healthcare? 2010, The Stockholm Network, [contrÔlé juillet 2013]. http://www.stockholm-network.org/downloads/publications/Sharing_the_Burden.pdf.
17. AIFA: La pratica clinica mette alla prova l'innovazione terapeutica: l'esempio «ivabradina». Rome, Italy, 2008. http://www.agenziafarmaco.gov.it/it/content/la-pratica-clinica-mette-alla-prova-l'innovazione-terapeutica-l'esempio-«ivabradina» [contrÔlé juillet 2013].
18. Goozner M. Concerns about provenge simmer as CMS ponders coverage. J Natl Cancer Inst 2011, 4:288-289. [contrÔlé juillet 2013]. http://jnci.oxfordjournals.org/content/103/4/288.full.
19. Chambers J.D., Pharm M., Neumann P.J. Listening to provenge-What a costly cancer treatment says about future Medicare policy. N Engl J Med 2011, 18:1687-1689.
20. Espín J., Rovira J., García L. Experiences and impact of european risk-sharing schemes focusing on oncology medicines. Rapport EMINET 2011, [contrÔlé juillet 2013]. http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/risksharing_oncology_012011_en.pdf.